Bottom Line: By strategically collaborating with commercial Integrated Delivery Networks on pharmaceutical management, the VA is...

The VA and DoD are not “loss leader” channels. They are high-value, margin-stable, influence-rich markets where a single, well-executed...

Pharmaceutical manufacturers frequently misinterpret market opportunity within the distinct VA patient population by directly applying...

We know both VA and DoD partner with Kaiser - but how do these health systems actually compare? If you’re investing in Kaiser Permanente,...

Bottom Line: Understanding the mechanisms in which a community care provider can request extended or new medical treatments is core...

Bottomline: The VA Community Care program, while crucial for expanding veteran healthcare access, can result in reimbursement...

Bottom Line: The Department of Defense (DoD) is frequently the first federal payer to formally assess newly FDA-approved pharmaceutical...

This side-by-side chart highlights the key distinctions between the VA healthcare system and Medicare, including eligibility, coverage...

Our team recently published Part II in a 3-part series aimed at helping drug manufactures gain an updated view of VA and DOD drug...

Bottom Line: The VA's updated presumptive conditions list expanding coverage for Gulf War and Post-9/11 veterans necessitates...

Bottom Line: Serving 2.8 million veterans at a $23.9 billion cost in FY2023, the VA Community Care Program expands healthcare access by...

Bottom Line: The VA's short-term community pharmacy Rx access isn't as open-ended as many assume. The Urgent/Emergent formulary contains...